[8-K] 4D Molecular Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

4D Molecular Therapeutics announced that it furnished a press release reporting its financial results for the three months ended June 30, 2025. The Form 8-K references a press release titled "4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones" as Exhibit 99.1 and includes an interactive data file as Exhibit 104. The company’s common stock trades on the Nasdaq Global Select Market under the ticker FDMT. The filing itself does not include numerical financial details in the text provided here; investors must consult Exhibit 99.1 for the full results and operational highlights.

Positive

• Press release furnished as Exhibit 99.1, indicating the company publicly disclosed its second quarter 2025 results and operational milestones.
• Interactive data file (Exhibit 104) provided, facilitating access to structured data for analysts and investors.

Negative

• No financial figures are included in the filing text provided; the Form 8-K references results for the three months ended June 30, 2025 but does not present revenue, EPS, cash, or other metrics within this text.

Insights

Financial Analyst

TL;DR: Routine disclosure; press release furnished announcing Q2 results for period ended June 30, 2025, but no financial figures appear in the filing text.

The Form 8-K notifies the market that 4DMT publicly released its second quarter 2025 results and related milestones via a press release furnished as an exhibit. Furnishing the press release satisfies public disclosure obligations and signals that detailed operating and financial metrics should be available in Exhibit 99.1. Because the filing text provided here contains no revenue, expense, profitability, cash balance, or guidance figures, this 8-K itself is informational rather than a source of quantitative assessment.

Corporate Governance Expert

TL;DR: The company complied with disclosure procedures by furnishing the press release and interactive data file; this is a routine, non-material update in isolation.

Furnishing the press release as Exhibit 99.1 and providing an Inline XBRL cover (Exhibit 104) are consistent with transparency and regulatory compliance for public companies. The filing informs stakeholders where to find the detailed results and operational milestones. In the absence of the exhibit’s contents, the 8-K does not on its own change the material picture for investors.

0001650648false00016506482025-08-112025-08-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2025

4D Molecular Therapeutics Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39782	47-3506994
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
5858 HORTON STREET #455
EMERYVILLE, California				94608
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 510 505-2680

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		FDMT		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 11, 2025, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the three months ended June 30, 2025. A copy of 4DMT’s press release, titled “4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones” is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Press Release, dated August 11, 2025, titled “4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones”
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			4D MOLECULAR THERAPEUTICS, INC.
Date:	August 11, 2025	By:	/s/ Uneek Mehra
			Uneek Mehra Principal Financial and Accounting Officer

FAQ

What did 4D Molecular Therapeutics (FDMT) disclose in this 8-K?

4DMT announced it furnished a press release reporting financial results for the three months ended June 30, 2025; that press release is included as Exhibit 99.1.

Does this 8-K include the numerical financial results for Q2 2025?

No. The filing text provided here does not include financial figures; investors should review Exhibit 99.1 for the detailed results and metrics.

Where is FDMT listed and what is the ticker symbol?

4D Molecular Therapeutics' common stock trades on the Nasdaq Global Select Market under the ticker FDMT.

Which exhibits were furnished with the Form 8-K?

Exhibit 99.1 (press release titled "4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones") and Exhibit 104 (cover page interactive data file).

Who signed the Form 8-K on behalf of 4DMT?

Uneek Mehra, Principal Financial and Accounting Officer, signed the filing included in the provided content.